1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
<b>T</b> O	
11 12	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza
11 12 13	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza
11 12 13 14	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza
11 12 13 14 15	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza Reyhaneh Zafarnejad <sup>1</sup> , Paul M. Griffin <sup>1</sup> , Mario Ventresca <sup>2</sup>
11 11 12 13 14 15 16	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza Reyhaneh Zafarnejad <sup>1</sup> , Paul M. Griffin <sup>1</sup> , Mario Ventresca <sup>2</sup>
11 12 13 14 15 16 17 18 19 20	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza Reyhaneh Zafarnejad <sup>1</sup> , Paul M. Griffín <sup>1</sup> , Mario Ventresca <sup>2</sup> <sup>1</sup> Department of Industrial and Manufacturing Engineering, Penn State University, University Park PA 16803, USA <sup>2</sup> School of Industrial Engineering, Purdue University, West Lafayette, IN 47906 USA
11 12 13 14 15 16 17 18 19 20 21	A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza Reyhaneh Zafarnejad <sup>1</sup> , Paul M. Griffin <sup>1</sup> , Mario Ventresca <sup>2</sup> <sup>1</sup> Department of Industrial and Manufacturing Engineering, Penn State University, University Park PA 16803, USA <sup>2</sup> School of Industrial Engineering, Purdue University, West Lafayette, IN 47906 USA

# 23 Abstract

Co-infection of COVID-19 and other respiratory pathogens, including influenza virus family, has 24 been of importance since the beginning of the recent pandemic. As the upcoming flu season arrives 25 in countries with ongoing COVID-19 epidemic, the need for preventive policy actions becomes 26 27 more critical. We present a joint compartmental SEIRS-SIRS model for the co-circulation of SARS-CoV-2 and influenza and discuss the characteristics of the model, such as the basic 28 reproduction number ( $R_0$ ) and cases of death and recovery. We implemented the model using 2020 29 30 to early 2021 data derived from global healthcare organizations and studied the impact of interventions and policy actions such as vaccination, guarantine, and public education. The 31 VENSIM simulation of the model resulted in  $R_0 = 7.5$ , which is higher than what was reported for 32 the COVID-19 pandemic. Vaccination against COVID-19 dramatically slowed its spread and the 33 34 co-infection of both diseases significantly, while other types of interventions had a limited impact on the co-dynamics of the diseases given our assumptions. These findings can help provide 35 guidance as to which preventive policies would be most effective at the time of concurrent 36 epidemics, and contributes to the literature as a novel model to simulate and analyze the co-37 38 circulation of respiratory pathogens in a compartmental setting that can further be used to study the co-infection of COVID-19 or similar respiratory infections with other diseases. 39

# 40 Keywords

41 SARS-CoV-2, Influenza, Co-infection, Compartmental Modeling, Vaccination, Quarantining.

42

# 44 **1. Introduction**

The recent pandemic pathogen, Severe Acute Respiratory Syndrome Coronavirus-2 45 (SARS-CoV-2), which started in December 2019, has caused a wide range of illness varying from 46 mild symptoms to complicated and severe respiratory response, and in 3% of cases even death<sup>1-3</sup>. 47 48 Although at the time of writing this paper available data was limited, recent case reports of concurrent infection of influenza virus in adults and children with SARS-CoV-2 infection have 49 suggested that co-infection may heavily influence morbidity and mortality<sup>4</sup>. Previous literature has 50 51 shown that co-infections were frequent in patient populations and is of importance for both flu season and deadly variants of SARS-CoV-2 <sup>5-8</sup>. The Centers for Disease Control and Prevention 52 (CDC) has reported that influenza and COVID-19 have overlapping signs and symptoms, and co-53 infection has been documented in both case reports and case series<sup>9</sup>. 54

55 The reported impact of existing infection with SARS-CoV-2 and co-infection with other pathogens 56 varies, from negative<sup>10</sup> to not significant<sup>11</sup> to positive<sup>12,13</sup>. For example, Kim et al. <sup>11</sup> reports more than 20% of 116 SARS-CoV-2 positive individuals tested over a 20 day period contained one or 57 58 more additional respiratory pathogens, most often rhinovirus/enterovirus and different types of 59 influenza virus family, although the prevalence of co-infection among COVID-19 positive and negative population was not statistically significant. In another study, Yue et al.<sup>12</sup> showed that the 60 prevalence of co-infection with influenza among a group of COVID-19 positive patients in Wuhan, 61 China was more than 50%, while the prevalence of infection with influenza virus pre-pandemic 62 63 was less than 1%. In a recent study, Bai et. al<sup>13</sup> found that influenza A virus (IAV) pre-infection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types through an 64 experimental co-infection with IAV and SARS-CoV-2 virus. 65

In terms of preventive policy actions during the recent pandemic, policy makers across the globe 66 designed different strategies to try to control the pandemic <sup>14</sup>. In the early stages of the pandemic, 67 while pharmaceutical interventions such as vaccination and medical treatment were not accessible. 68 non-pharmaceutical interventions were widely implemented<sup>15</sup>. These interventions, such as mask 69 mandates, social distancing, quarantining, surveillance testing, and contact tracing were 70 substantially effective in slowing down the progression of COVID-19<sup>16-18</sup> and some of them are 71 still in place to date. These non-pharmaceutical interventions were found to reduce the burden of 72 flu as well<sup>19</sup>, intuitively due the similarities in respiratory propagation of both viruses and how the 73 74 parallel spread of diseases were slowed down by general hygiene enforcement and social contact reduction. Vaccination programs for COVID-19, becoming accessible worldwide midway through 75 the pandemic, played a significant role in reducing the spread of COVID-19, and associated 76 hospitalization and mortality<sup>20</sup>. With the emergence of new variants of COVID-19, vaccination 77 proved to be as impactful although booster doses were required and remain ongoing globally<sup>21</sup>. 78 However, with the rise of new variants, achieving herd immunity still remains out of reach <sup>22</sup>. 79 Nevertheless, flu shots are promoted by public health officials and are found to be effective in 80 controlling simultaneous outbreak of influenza and COVID-1923. However, it is unclear how 81 impactful pharmaceutical interventions are in reducing co-infection cases of COVID-19 and 82 influenza. 83

Understanding the co-existence and co-infection of two or more diseases at the same time has been an important and controversial topic in the field of epidemiology. To name a few, in 2016, Naji and Hussein<sup>24</sup> proposed a compartmental model describing the dynamics of the spread of two different types of pathogens based on two underlying models of disease spread, an SIS-type disease and an SIRS-type disease. In another study, Tilahun et. al<sup>25</sup> studied the co-dynamics of Pneumonia

as an airborne disease and Typhoid fever as a vector-based disease using a joint SIRS-SIRS simulation for cost-effective disease control purposes. More recently, Rehman et. al<sup>26</sup> developed a mathematical transmission model for the co-infection of dengue fever and COVID-19, and described the co-dynamics of the propagation using qualitative and numerical analysis. However, there is limited literature on modeling the co-existence and co-circulation of SARS-CoV-2 and influenza viruses as two airborne diseases.

In this paper, we describe a model of disease progression consisting of two joint compartmental 95 models for COVID-19 and influenza. We further simulate the behavior and transmission dynamics 96 of diseases based on the most recent data including US COVID-19 updates and CDC and WHO 97 guidelines. Moreover, we discuss how our results compare and contrast with observed data and 98 published literature since the COVID-19 pandemic started. Finally, we study the impact of 99 vaccination against COVID-19, and non-pharmaceutical interventions such as education and 100 social distancing on the behavior of COVID-19 – influenza co-circulation. The results of this study 101 102 could provide useful information for researchers and policy makers as to which policy action could 103 mitigate the negative impacts of concurrent epidemics on mortality rate and total cases of infection. 104 With the possibility of emergence of other respiratory epidemics and pandemics in the future<sup>27</sup>, 105 mathematical and predictive models of co-infection with multiple diseases could further be used in cost-effectiveness and cost-utility analyses and help develop adaptive and effective policy 106 actions. 107

**2. Materials and Methods** 

109 We proposed a SEIRS-SIRS compartmental model to study the co-existence of COVID-19 and 110 influenza and further implemented the Next Generation Method (NGM) to find the basic

reproduction rate ( $R_0$ ). We also performed sensitivity analysis and solved the model for various parameter values in order to understand the effect of interventions and policy actions on the spread of diseases <sup>28</sup>. We created a simulation model for validation and additional investigations.

114

## 2-1. Model Parameters and Relationships

To capture the co-dynamics of COVID-19 and influenza, we developed a joint SEIRS-SIRS 115 compartmental model (Figure 1). This model considers a population (N) that is divided into nine 116 117 compartments, susceptible (S), COVID-19 exposed ( $E_c$ ), COVID-19 infectious ( $I_c$ ), influenza infectious (I<sub>f</sub>), COVID-19 and influenza co-infectious (I<sub>fc</sub>), COVID-19 and influenza co-exposed 118 (E<sub>fc</sub>), COVID-19 recovered (Rc), influenza recovered (R<sub>f</sub>) and COVID-19–influenza co-infectious 119 recovered (R<sub>fc</sub>). We assumed a closed environment with birth rate and natural death rates both 120 equal to 0, while the number of susceptible population increases by those individuals that lose their 121 temporary immunity<sup>29</sup> from the recovered compartment of COVID-19 ( $R_c$ ), influenza ( $R_f$ ) and 122 COVID-19–influenza co-infected compartment ( $R_{fc}$ ) with rates of  $\delta_1$ ,  $\delta_2$  and  $\delta_3$ , respectively. 123

Figure 1 – Schematic flow of the model, parameters and compartments are outlined in section 4.1 and dynamics are
 described in section 4.2. Different colors are utilized to indicated similar components.

Susceptible individuals become infected either with COVID-19 at the rate  $\gamma_c$  and join the COVID-19 exposed compartment (E<sub>c</sub>), or with influenza at infection rate  $\gamma_f$  and joining influenza infectious compartment (I<sub>f</sub>). Patients that are exposed to COVID-19 will become infectious after the latent period (L<sub>c</sub>). Since the latent period for influenza is relatively low (roughly from 0.64<sup>30</sup> days to 1.6 days<sup>31</sup>), we ignored the latency period for influenza. Similarly, patients already infected with influenza might get infected with COVID-19 with the co-infection rate  $\gamma_{fc}$  and become COVID-19 exposed, and after the latent period become co-infected.

The infectious compartment of COVID-19 can receive treatment or recover naturally at the rate  $\beta_c$ 133 and move to COVID-19 recovered compartment ( $R_c$ ) or die with a death rate of  $\alpha_c$ . Similarly, the 134 infected compartment of influenza can receive treatment or recover with a rate of  $\beta_f$  and join the 135 influenza recovered compartment ( $R_f$ ) or die at a rate of  $\alpha_f$ . Moreover, the COVID-19- influenza 136 co-infected compartment transitions from the co-infected compartment to the recovered 137 138 compartment with a rate of  $\beta_{fc}$  and obtain temporary immunity and therefore join the co-infected recovered compartment (R<sub>fc</sub>). We assumed that all recovered compartments tend to become 139 susceptible once again, after a specific amount of time ( $\delta_f$ ,  $\delta_c$  and  $\delta_{fc}$  for flu recovered, COVID-19 140 recovered and co-infection recovered, respectively). 141

An important assumption we made is considering adjustment parameters,  $k_1$ ,  $k_2$  and  $k_3$  as 142 143 additional coefficients in the model. Since this model is essentially the combination of two disjoint SEIRS and SIRS compartmental models, overlaps are inevitable. Patients might technically belong 144 145 to more than one compartment in reality, but these models are unable to easily capture this complexity. For the model to produce valid results, we assumed that only a proportion of COVID-146 19 or influenza infected individuals are at risk for co-infected with the other pathogen, and 147 therefore assigned adjustment probabilities<sup>25,26</sup>. These additional parameters control the flow 148 between compartments and adjust the daily per capita co-infection rate and recovery rates so that 149 the resulting trends mimic real world observations. Adjustment parameters received values 150 151 between 0 and 1 with the sum of 1.

152

## 5-1. Mathematical Model and adjustments

153 
$$\frac{dS}{dt} = \delta_c R_c + \delta_f R_f + \delta_{fc} R_{fc} - \frac{\gamma_c I_c S}{N} - \frac{\gamma_f I_f S}{N} eq -1$$

154 
$$\frac{dE_c}{dt} = \frac{\gamma_c I_c S}{N} - \frac{E_c}{L_c}$$
 eq -2

155 
$$\frac{dI_c}{dt} = \frac{E_c}{L_c} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_c + \alpha_c) I_c q$$
 eq - 3

156 
$$\frac{dI_f}{dt} = \frac{\gamma_f I_f S}{N} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_f + \alpha_f) I_f \qquad \text{eq} - 4$$

157 
$$\frac{dE_{fc}}{dt} = \frac{k_1 \gamma_{fc} l_f l_c}{N} - \frac{E_{fc}}{L_c} \qquad \text{eq} - 5$$

158 
$$\frac{dI_{fc}}{dt} = \frac{E_{fc}}{L_c} + \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_3 \beta_{fc} + \alpha_{fc}) I_{fc}$$
 eq -6

159 
$$\frac{dR_c}{dt} = k_2 \beta_c I_c - \delta_c R_c \qquad \text{eq} - 7$$

$$160 \quad \frac{dR_f}{dt} = k_2 \beta_f I_f - \delta_f R_f \qquad \text{eq} - 8$$

161 
$$\frac{dR_{fc}}{dt} = k_3 \beta_{fc} I_{fc} - \delta_{fc} R_{fc} \qquad \text{eq} - 9$$

162 
$$N = S + E_c + E_{fc} + I_f + I_c + I_{fc} + R_f + R_c + R_{fc}$$
 eq -10

#### 163 **2-2. Basic Reproduction Number (R<sub>0</sub>)**

The Basic Reproduction Number  $(R_0)$  is used to measure the transmission potential of a disease 164 165 and is equal to the average number of secondary infections produced by a typical case of an infection in a population where everyone is susceptible<sup>32,33</sup>. The next generation method is used to 166 calculate the R<sub>0</sub> associated with the model of co-infection of SARS-CoV-2 and influenza virus<sup>34</sup>. 167 This system has five infected states: E<sub>c</sub>, E<sub>fc</sub>, I<sub>c</sub>, I<sub>f</sub> and I<sub>fc</sub>; and four uninfected states: S, R<sub>c</sub>, R<sub>f</sub> and 168 R<sub>fc</sub>. Although there are nine states in the model, it is eight-dimensional as the total population size 169 is constant. At the infection-free steady state,  $E_c = E_{fc} = I_c = I_f = I_{fc} = R_c = R_f = R_{fc} = 0$ , hence S = 170 N. Therefore, for small (E<sub>c</sub>, E<sub>fc</sub>, I<sub>c</sub>, I<sub>f</sub>, I<sub>fc</sub>) we have the following non-linear system 171

172 
$$\frac{dE_c}{dt} = \frac{\gamma_c I_c S}{N} - \frac{E_c}{L_c}$$
eq - 11

173 
$$\frac{dE_{fc}}{dt} = \frac{k_1 \gamma_{fc} I_f I_c}{N} - \frac{E_{fc}}{L_c} \qquad \text{eq} - 12$$

174 
$$\frac{dI_c}{dt} = \frac{E_c}{L_c} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_c + \alpha_c) I_c \qquad \text{eq} - 13$$

175 
$$\frac{dI_f}{dt} = \frac{\gamma_f I_f S}{N} - \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_2 \beta_f + \alpha_f) I_f \qquad \text{eq} - 14$$

176 
$$\frac{dI_{fc}}{dt} = \frac{E_{fc}}{L_c} + \frac{k_1 \gamma_{fc} I_f I_c}{N} - (k_3 \beta_{fc} + \alpha_{fc}) I_{fc} \qquad \text{eq} - 15$$

177 The transition (F) and transmission (V) matrices are as follows:

178

180 and 
$$V = \begin{pmatrix} \frac{1}{L_c} & 0 & 0 & 0 & 0 \\ 0 & \frac{1}{L_c} & 0 & 0 & 0 \\ -\frac{1}{L_c} & 0 & k_2\beta_c + \alpha_c & 0 & 0 \\ 0 & 0 & 0 & k_2\beta_f + \alpha_f & 0 \\ 0 & -\frac{1}{L_c} & 0 & 0 & k_3\beta_{fc} + \alpha_{fc} \end{pmatrix}$$
 eq -17

181 The eigenvalues of  $FV^{-1}$  are obtained as:

182  $\lambda_1^* = 0$  eq -18

184 
$$\lambda_3^* = 0$$
 eq - 20

185 
$$\lambda_4^* = \frac{\gamma_c}{k_2 \beta_c + \alpha_c}$$
 eq -21

186 
$$\lambda_5^* = \frac{\gamma_f}{k_2 \beta_f + \alpha_f}$$
  
187 eq - 22

188 The basic reproduction number is computed as the spectral radius of  $FV^{-1}$ 

189 
$$R_0 = \max\{\lambda_1^*, \lambda_2^*, \lambda_3^*, \lambda_4^*, \lambda_5^*\} = \max\{\lambda_4^*, \lambda_5^*\}$$
 eq -23

which after simplification is independent from the co-infection rate ( $\gamma_{fc}$ ) and co-infection recovery rate ( $\beta_{fc}$ ), and depending on the evaluating parameters, the dominant R<sub>0</sub> is merely determined by either COVID-19 or influenza branch. We discuss the implications of R<sub>0</sub> in Section 2-2.

#### **2-3.** Simulation

In order to study the co-spread of COVID-19 and influenza based on the proposed model, we 195 developed a system dynamics simulation model in VENSIM software V 8.0.9<sup>35</sup>. The full model 196 is provided in Appendix 1 and more details will be provided on request. Table 1 summarizes the 197 parameter values and available references implemented in the simulation. We modeled the co-198 infection of SARS-CoV-2 for the state of Indiana with the population of 6,732,000 according to 199 2019 US census<sup>36</sup>. The parameter values are derived form 2020 available COVID-19 dashboards 200 201 and databases. We made necessary assumptions in cases where convenient or proper data was not accessible, the most important of which is the estimation of co-infection rate. As discussed 202 previously in the Introduction, it is still unclear whether infection with COVID-19 or other 203 204 respiratory pathogens affects the co-infection rate. By roughly estimating the average of values

reported in the literature, we assumed that the daily per person co-infection rate is 20% more than

the maximum of infection rate with either COVID-19 or influenza. The rest of the parameters,

references and assumptions are provided in Table 1.

208

#### Table 1 – Model parameters summary

	Param eter	Value	Description	Reference
ompartments	N	~ 6,732,000	Population (Indiana)	36
	S	195,732	Susceptible population	N - $I_c - I_f - I_{fc}$
	Ec	0	COVID-19 exposed	SEIRS model assumption
	E <sub>fc</sub>	0	influenza infected and COVID-19 exposed	SEIRS model assumption
	Ic	1	COVID-19 infectious	SEIRS model assumption
	I <sub>f</sub>	1	influenza infectious	SIRS model assumption
0	I <sub>fc</sub>	1	COVID-19 an influenza co-infectious	SEIRS model assumption
	R <sub>c</sub>	0	Recovered compartment of COVID-19	SEIRS model assumption
	R <sub>f</sub>	0	Recovered compartment of influenza	SIRS model assumption
	R <sub>fc</sub>	0	Recovered compartment of both diseases	SEIRS model assumption
	$\delta_{ m c}$	1/365 (day-1)	Rate of moving from recovered state to susceptible state – COVID-19	48
	$\delta_{ m f}$	1/180 (day-1)	Rate of moving from recovered state to susceptible state – influenza	48
	$\delta_{ m fc}$	1/365 (day-1)	Rate of moving from recovered state to susceptible state – both diseases	Assumption (max of $\delta_{\rm c}$ and $\delta_{\rm f}$ )
	γc	0.60756 (person <sup>-1</sup> day <sup>-1</sup> )	Transmission rate – COVID-19	49
	$\gamma_{ m f}$	$\sim 0.44605 \text{ (person}^{-1} \text{ day}^{-1}\text{)}$	Transmission rate – influenza	<sup>50</sup> – assumption (At least 20% less contagious than COVID-19)
ters	$\gamma_{ m fc}$	Max {1.2 * $\gamma$ } = 0.72 (person <sup>-1</sup> day <sup>-1</sup> )	Transmission rate – co-infection	Assumption (~1.2 times more than healthy people)
arame	$\beta_{\rm c}$	0.10013 (person <sup>-1</sup> day <sup>-1</sup> )	Recovery rate - COVID-19	50
P	$m{eta}_{ m f}$	0.2 (person <sup>-1</sup> day <sup>-1</sup> )	Recovery rate – influenza	51
	$eta_{ m fc}$	0.1 (person <sup>-1</sup> day <sup>-1</sup> )	Recovery rate – Both diseases	Assumption
	L <sub>c</sub>	2.5 (days, on average)	Latent period associated with COVID- 19	15
	$\alpha_{\rm c}$	0.0007 (person <sup>-1</sup> day <sup>-1</sup> )	Death rate due to COVID-19	52
	$lpha_{ m f}$	0.0002 (person <sup>-1</sup> day <sup>-1</sup> )	Death rate due to influenza	<sup>53</sup> – Assumption
	$lpha_{ m fc}$	0.0007 * 2.27 (person <sup>-1</sup> day <sup>-1</sup> )	Death rate due to Co-infection	54
	v	0.01 to 0.1 (person <sup>-1</sup> day <sup>-1</sup> )	Vaccination rate against COVID-19	44

$k_1$	0.2	Adjustment coefficient	<sup>11</sup> , Assumption
$k_2$	0.8	Adjustment coefficient	1 - <i>k</i> <sub>1</sub>
<i>k</i> <sub>3</sub>	1-0.431	Adjustment coefficient	<sup>11</sup> , Assumption

209

#### 210 **2-4.** Interventions

The simulation was analyzed for three modified versions of the model to capture the impact of 211 different intervention settings. The primary model (i.e. the baseline model) assumes COVID-19 212 213 and influenza propagation began simultaneously at T=0. The second model includes vaccination against COVID-19 as a pharmaceutical intervention, and the third model considers the impact of 214 non-pharmaceutical interventions, such as quarantining, public education and social distancing. 215 216 Although the flu occurs mostly as a seasonal disease, for the sake of simplicity we assumed simultaneous propagation of both COVID-19 and influenza. We simulated the co-circulation of 217 COVID-19 and influenza for 365 days, for an initial population of  $S_0 = 6,732,000$ . The initial value 218 for all other compartments was assumed to be 0 at time T=0, except for the infected compartment 219 220 which initially contains 1 patient (local patient zero).

In terms of the mathematical structure of the model, the impact of vaccination and quarantining/public education is described as follows. Vaccination against COVID-19 increases the rate of exit from the susceptible subgroup:

224 
$$\frac{dS}{dt} = \delta_c R_c + \delta_f R_f + \delta_{fc} R_{fc} - \frac{\gamma_c I_c S}{N} - \frac{\gamma_f I_f S}{N} - V.S \qquad \text{eq} - 24$$

225 
$$\frac{dR_c}{dt} = \mathbf{V}.\mathbf{S} + k_2\beta_c I_c - \delta_c R_c \qquad \text{eq} - 25$$

where V indicates the vaccination rate (person<sup>-1</sup> day<sup>-1</sup>)  $day^{-1}$ 

227 Quarantining/public education on the other hand affects the rate of infection with COVID-19,

influenza as well as the rate of co-infection, through decreasing the contact rate between

229 individuals:

$$\gamma_c^{New} = \mathbf{D}.\gamma_c \qquad \text{eq} - 2\mathbf{e}$$

$$\gamma_{fc}^{New} = \boldsymbol{D}.\gamma_{fc} \qquad \text{eq} - 28$$

where D indicates the decrease in contact rate. The rest of the mathematical model remainsunchanged.

235

# 236 **3. Results**

# 237 **3-1. Baseline Model Simulation Results**

Figure 2 shows an overview of all the compartments present in the model over the course of the 238 simulation, as well as a detailed comparison between compartments. The parameter values were 239 derived from 2020 and early 2021 national and global databases. As demonstrated in Figure 2 and 240 the corresponding subfigures, in the base model with no interventions, the peak for infection of 241 COVID-19 was significantly higher than for influenza and co-infection of both. The three peaks 242 almost occurred at the same period, with a lower peak for the influenza in comparison to COVID-243 19 and a dramatically lower peak for co-infection in comparison to the other types of infection. 244 Despite similarities between SARS-CoV-2 and influenza virus family, the transmission rate 245 246 associated with COVID-19 was at least 20 percent (to up to 3 times) higher than influenza. This is why we see a clearly smaller peak of infection associated with influenza. 247

Figure 2 – An overview of the compartments in the model. The smaller figures illustrate a closer comparison
between similar compartments, for a 365-day simulation of the Co-infection of COVID-19 and Influenza.

A second and smaller peak in the COVID-19 infected population occurred after around 150 days of the first peak, which is in accordance with previously published data for the US from February 20, 2020 to December 21, 2020<sup>37</sup>. No such behavior was found in association with influenza, which also agrees with the expected behavior of annual influenza epidemy in Indiana population<sup>38</sup> prior to any COVID-19 related interventions.

On the other hand, the recovered compartment of COVID-19, influenza, and co-infection of both behave differently over time. Three existing recovered compartments (recovered from COVID-19, influenza, or the co-infection of both), experienced a peak at around the same time (COVID-19 is behind due to the incubation period), similar to the infected compartment with the COVID-19 recovered population with a significantly higher peak (due to more cases of infection). We can see that based on this model for a 365-day simulation, after around 9 months almost exclusively COVID-19 remains active and contagious, particularly after the second wave.

The susceptible and deceased compartments also showed interesting underlying behaviors over 262 the course of the simulation. Over the first year of pandemic, over 96% of the susceptible 263 population suffered from at least one of the infections which is relatively high. The smaller rise in 264 the susceptible population occurred exactly before the second wave of the COVID-19 pandemic 265 (T = 229 days). This indicates that before the second wave, the number of individuals in the 266 susceptible compartment increased due to recruitment of susceptible individuals by recovery. 267 268 Consequently, the second wave appeared, and an additional number of infected individuals led to another less steep fall in the number of susceptible individuals. The same behavior was observed 269 for the number of deceased populations, more COVID-19 infected individuals in the second wave 270

led to more deaths due to COVID-19, while the number of deaths caused by influenza remained
the same (~3481), with a very slight increase for individuals infected with both diseases (~100
additional deaths).

The simulated death rates and observed trends also mimic recent observations both in the US in general and Indiana<sup>37</sup>, as the first and second wave in the total COVID-19 deaths during 2020 indicates how well this model compares with the published literature.

#### **3-2.** Calculation of $R_0$

Given the information and parameter values provided in Table 1, the basic reproduction number  $(R_0)$  can be estimated for the model based on Eq. 23. In this case, we have

280 
$$R_0 \approx \max\{0,0,0,2.8,7.5\} = 7.5$$

which in comparison to the median  $R_0$  associated with COVID-19 in the US (5.8 - 95% CI 3.8-8.9)<sup>39,40</sup> in 2020 and early 2021, as well as  $R_0$  associated with seasonal flu  $(1.2 - 1.3)^{41}$  indicates higher contagiousness of COVID-19 and influenzas co-circulation.

#### 284 **3-3.** Interventions and Policy Actions

To model vaccination against COVID-19, we assumed a transition between the susceptible compartment and the COVID-19 recovered compartment. Individuals in the susceptible group can either get infected by COVID-19 or influenza, or directly go to COVID-19 recovered compartment based on a vaccination rate. Therefore, by running sensitivity analysis on the model with various vaccination rates we estimated the impact of vaccination on co-circulation of infections. On the other hand, quarantine and education of people both were assumed to reduce the number of contacts, mostly among the susceptible population, resulting in a reduction in the rates of infection

292 ( $\gamma$ ). In other words, we studied two types of interventions: those affecting the number of contacts 293 per person per day, and those affecting the transition between stages by adding new transition 294 states.

295 2-3-1. Vaccination against COVID-19

296 By April 2021, the US has administered more than 3 million vaccine shots per day, or around 0.01 297 shots per person daily across the country<sup>33</sup>. To study the impact of vaccination against COVID-19, we defined a varying range for vaccination rate for the state of Indiana, ranging from 0 to 0.005298 299 (person per day) and further ran sensitivity analysis on the impact of vaccination rate on the model. Figure 3 demonstrates how sensitive the size of each compartment is to the rate of vaccination. As 300 the rate of vaccination increased, a visible decrease in the number of infected individuals could be 301 identified; daily flu infection and COVID19 - flu co-infection cases decline for at least 85% as the 302 daily per capita vaccination rate increases by 0.0005 person.day<sup>-1</sup>. This in fact is in accordance 303 with the minute level of reported flu cases in 2020 and early 2021<sup>42</sup>. Similarly, yet more slowly 304 for the COVID-19 daily case, with a 0.001 increase in daily per capita vaccination rate there was 305 a 45% reduction in the total number COVID-19 infected individuals. The second wave of COVID-306 19 was also mitigated as the vaccination rate increased. The total number of deaths also decreased 307 with the higher prevalence of vaccination. The impact of vaccination was more pronounced on the 308 influenza and co-infection compartments, which can be justified due to lower incubation rate 309 310 associated with influenza in comparison to COVID-19.

An important point to consider here is the fact that, in this setting, higher vaccination rates corresponded to faster transitions between the susceptible compartment and the COVID-19 recovered compartment. As mentioned previously, from the modeling perspective, vaccination

plays the role of a shortcut from susceptible compartment to recovered compartment. That is why there is a fall in the number of susceptible individuals as the rate of vaccination against COVID-19 increases. This also affects the total number of COVID-19 recovered individuals, which is not entirely due to infection.

Figure 3 – The effect of COVID-19 vaccine on the simulation results – lighter curves indicate smaller rate of
 vaccination.

320 *2-3-2. Quarantine and education* 

In order to study the impact of non-pharmaceutical interventions such as quarantine and 321 education<sup>43</sup>, we assumed that the contact rate per person can decrease by up to 80% by guarantining 322 non-infected individuals, social distancing and educating the public. This assumption is made to 323 enable the model to capture a wide range of contact rates, without considering the feasibility of 324 providing so in practice. In this case, the simulation structure remains the same as the original 325 simulation except for the values of  $\gamma_f$ ,  $\gamma_c$  and  $\gamma_{fc}$  will be reduced by up to 20% of the original 326 values, in increments of 10 percent. As shown in Figure 4, as the contact rate declined from 1 327 328 (100%) to 0.2 (20%), the total number of deceased individuals dropped dramatically in all the 329 deceased compartments. Similarly, the peak for influenza infection and COVID-19 - influenza 330 infection dampened as the number of contacts decreased. For example, a 50% reduction in the contact rate resulted in more than a 90% reduction in the daily cases of influenza and co-infection 331 332 and led to a delay of around 75 days in the peak of COVID-19 propagation. However, in the case 333 of individuals with COVID-19 only, the primary effect of the reduction in contact rate was a delayed peak. As the contact rate decreased (from 70% of the maximum effective contact rate to 334 20%), we observed more than 60% reduction in the peak of COVID-19 cases as well. 335

Like what was observed through vaccination, changes in the contact rate induced similar behavior 336 in the model, such as the short-term increase (for a window of about 100 days) in the peak of 337 COVID-19 infection. Similar behavior was found in other compartments of COVID-19 infection 338 branch as well, and in all cases the peak occurred later in time. We can explain this behavior based 339 on both the model structure and assumptions. Here we noticed a steady reduction in influenza 340 341 infection cases and the number of cases in other influenza related compartments, which indicates the sensitivity of influenza to the contact rate, unlike COVID-19 with a short term increase and 342 further decrease behavior. Since fewer patients moved from the susceptible compartment to the 343 influenza infected compartment (up to 60% less in comparison to COVID-19 cases at the peak). 344 more individuals would remain susceptible and further move to the COVID-19 exposed and 345 infected compartments. This is a weakness of compartment models per se, which prevents 346 individuals from belonging to multiple compartments at the same time. Therefore, we cannot rely 347 on these results to estimate how well education and guarantining can reduce the speed of infection. 348 349 However, we can claim that reducing the contact rate was associated with delay in when the peak in infection curve occurred. 350

Figure 4 – The effect of quarantine and education on the simulation results – lighter curves indicate higher decrease
in the contact rates (1: no decrease in contact rates, 0.2: 20% of the maximum effective contact rate, etc.)

# 353 **4. Discussion**

In this paper, the co-circulation of SARS-CoV-2 and influenza was studied using a joint SEIRS-SIRS compartmental model, including the impact of various interventions and policy actions. In addition, the basic reproduction number associated with the co-infection of COVID-19 and influenza was computed and found to be heavily influenced by the COVID-19 branch. The basic

reproduction number computed based on the model ( $\sim$ 7.5) was also higher in comparison to R<sub>0</sub> associated with COVID-19 or influenza separately, pointing to the importance of understanding and mitigating co-infection.

In terms of interventions, the effect of interventions such as vaccination against COVID-19 was 361 found to be significant in controlling the spread of COVID-19 alongside seasonal flu, with more 362 than a 65% reduction in the total number of deceased individuals per year based on a vaccination 363 rate of 3 susceptible individuals out of 1000 per day. Other types of interventions that affect the 364 rate of transmission were not as successful as vaccination in reducing the total number of infected 365 366 and deceased individuals but did effectively delay the peak in infection. Both interventions resulted in significant decrease in the number of flu cases, which is what was observed in  $2020^{42}$ . This 367 368 implies that preventive interventions against COVID-19, pharmaceutical or non-pharmaceutical, automatically reduced the effect of other circulating respiratory pathogens such as influenza virus 369 family. 370

There are several limitations to our work. For the sake of simplicity, we made several assumptions 371 such as negligible incubation period for influenza, adjustment coefficients, and vaccination only 372 against COVID-19, and parameterized the model with data from the developing, and in some cases 373 contradicting, literature on the ongoing COVID-19 pandemic. Moreover, we limited the simulation 374 to a closed environment with natural rates of birth and death equal to zero, as well as a 365-day 375 376 simulation period that could lead to missing patterns of disease propagation and multiple waves that might occur over a period longer than a year. The model also only accounts for simultaneous 377 co-infection and not sequential infection for periods shorter than 6 months (the recovery period of 378 379 influenza) which could lead to biased simulation results. Another limitation to this work is that the influenza virus family was considered to be a seasonal infection, usually occurring in the fall 380

and winter<sup>44</sup> with a year-round circulation (with an expected peak between December and February in the US). On the other hand, there is lack of agreement in the literature over whether infection with influenza can potentially block infection with COVID-19<sup>13,45,46</sup>, in this model we only focused on the possibility of higher co-infection rates among patients infected with other pathogens. Further research could increase the accuracy of the current model by relaxing some of those assumptions.

Despite these limitations, our model successfully mimicked the observed patterns of COVID-19 387 and flu infections throughout 2020 and early 2021, when the COVID-19 pandemic was still away 388 from an endemic phase. For future work, considering a simple cost-and-effect analysis, this model 389 can assist healthcare policy makers to design and establish more efficient and less costly 390 interventions to control the co-spread of such diseases<sup>36</sup>. In the times of deadly pandemics such 391 the recent COVID-19 pandemic, making cost-effective decisions regarding control policies can 392 heavily determine how well the economy can tolerate the impacts associated with such chaotic 393 394 situations.

# **5.** Conclusion

The simulation analysis presented in this work could provide public health officials with modeling tools and information that will help them to issue proper preventive guidelines and policy actions for the upcoming flu season in the southern hemisphere, and particularly in countries with yet ongoing COVID-19 crisis. Moreover, this work contributes to the current literature by introducing a novel epidemic model for simulating the co-dynamics of respiratory infection with two or more infectious pathogens, and has applicability in other settings including co-infection of Sexually Transmitted Diseases (STDS), Human Immunodeficiency Virus (HIV), Bacterial Pneumonia, etc.

403

# 404 **Author contribution**

RZ helped define the problem, helped develop the model, ran the simulations, and helped in the
writing of the manuscript. MV helped define the problem, helped interpret the results, and helped
in the writing of the manuscript. PG helped interpret the results and helped in the writing of the
manuscript.

# 409 Supporting information

- 410 The VENSIM simulation models used during the current study are available and can be found at
- 411 <u>https://github.com/Rey-</u>
- 412 Zafarnejad/A Joint Compartmental Model for The Coinfection of SARSCoV2 and Influen
- 413 <u>za.</u> Further details on the model and simulation can be provided upon request.

# 415 **References**

- 416 1. Asch, D. A. et al. Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19
- 417 During the First 6 Months of the Pandemic. *JAMA Internal Medicine* **181**, 471–478 (2021).
- 418 2. Fontanet, A. et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet 397, 952–
- 419 954 (2021).
- 420 3. Mortality Analyses. Johns Hopkins Coronavirus Resource Center
- 421 https://coronavirus.jhu.edu/data/mortality.
- 422 4. Calcagno, A. et al. Coinfection with other respiratory pathogens in COVID-19 patients. Clinical
- 423 *Microbiology and Infection* **0**, (2020).
- 424 5. Awan, U. A. *et al.* COVID-19 and influenza H1N1: A dangerous combination for Pakistan in the
  425 upcoming winter season. *Journal of Medical Virology* 93, 1875–1877 (2021).
- 426 6. Jing, R. *et al.* Co-infection of COVID-19 and influenza A in a hemodialysis patient: a case report.
  427 *BMC Infectious Diseases* 21, 68 (2021).
- 428 7. Kawai, S. *et al.* How many coinfected patients with influenza and COVID-19 are there in a single
- 429 Japanese hospital during the first wave? *Japanese Journal of Infectious Diseases* advpub, (2021).
- 430 8. del Rio, C., Omer, S. B. & Malani, P. N. Winter of Omicron—The Evolving COVID-19 Pandemic.
  431 *JAMA* 327, 319–320 (2022).
- 432 9. Nowak, M. D., Sordillo, E. M., Gitman, M. R. & Mondolfi, A. E. P. Coinfection in SARS-CoV-2
  433 infected patients: Where are influenza virus and rhinovirus/enterovirus? *Journal of Medical Virology*434 92, 1699–1700 (2020).
- 435 10. Stowe, J. et al. Interactions between SARS-CoV-2 and Influenza and the impact of coinfection on
- 436 *disease severity: A test negative design.* http://medrxiv.org/lookup/doi/10.1101/2020.09.18.20189647
- 437 (2020) doi:10.1101/2020.09.18.20189647.
- 438 11. Kim, D., Quinn, J., Pinsky, B., Shah, N. H. & Brown, I. Rates of Co-infection Between SARS-CoV-2
  439 and Other Respiratory Pathogens. *JAMA* 323, 2085 (2020).

- 440 12. Yue, H. et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and
- 441 influenza viruses in patients during COVID-19 outbreak. *Journal of Medical Virology* 92, 2870–2873
  442 (2020).
- 443 13. Bai, L. *et al.* Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. *Cell Research*444 31, 395–403 (2021).
- 445 14. Hsiang, S. *et al.* The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature*446 584, 262–267 (2020).
- 447 15. CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention
- 448 https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html (2020).
- 16. Soltesz, K. et al. The effect of interventions on COVID-19. Nature 588, E26–E28 (2020).
- 450 17. Zafarnejad, R. & Griffin, P. M. Assessing school-based policy actions for COVID-19: An agent-
- 451 based analysis of incremental infection risk. *Computers in Biology and Medicine* **134**, 104518 (2021).
- 452 18. Ge, Y. et al. Impacts of worldwide individual non-pharmaceutical interventions on COVID-19
- 453 transmission across waves and space. International Journal of Applied Earth Observation and
- 454 *Geoinformation* **106**, 102649 (2022).
- 455 19. Fricke, L. M., Glöckner, S., Dreier, M. & Lange, B. Impact of non-pharmaceutical interventions
- 456 targeted at COVID-19 pandemic on influenza burden a systematic review. *Journal of Infection* 82,
  457 1–35 (2021).
- 458 20. Moghadas, S. M. *et al.* The impact of vaccination on COVID-19 outbreaks in the United States.
   459 *medRxiv* 2020.11.27.20240051 (2021) doi:10.1101/2020.11.27.20240051.
- 460 21. Buchan, S. A. et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic
- 461 infection and severe outcomes. 2021.12.30.21268565 Preprint at
- 462 https://doi.org/10.1101/2021.12.30.21268565 (2022).
- 463 22. Kashte, S., Gulbake, A., El-Amin III, S. F. & Gupta, A. COVID-19 vaccines: rapid development,
- 464 implications, challenges and future prospects. *Human Cell* **34**, 711–733 (2021).

- 23. Paget, J. *et al.* The impact of influenza vaccination on the COVID-19 pandemic? Evidence and
  lessons for public health policies. *Vaccine* 38, 6485–6486 (2020).
- 467 24. Naji, R. K. & Hussien, R. M. The Dynamics of Epidemic Model with Two Types of Infectious
  468 Diseases and Vertical Transmission. *Journal of Applied Mathematics* 2016, 1–16 (2016).
- 469 25. Tilahun, G. T., Makinde, O. D. & Malonza, D. Co-dynamics of Pneumonia and Typhoid fever
- 470 diseases with cost effective optimal control analysis. *Applied Mathematics and Computation* **316**,
- 471 438–459 (2018).
- 472 26. Rehman, A. ul, Singh, R. & Agarwal, P. Modeling, analysis and prediction of new variants of covid-
- 473 19 and dengue co-infection on complex network. *Chaos, Solitons & Fractals* **150**, 111008 (2021).
- 474 27. Gray, G. C., Robie, E. R., Studstill, C. J. & Nunn, C. L. Mitigating Future Respiratory Virus
- 475 Pandemics: New Threats and Approaches to Consider. *Viruses* **13**, 637 (2021).
- 476 28. Dimitrov, N. B. & Meyers, L. A. Mathematical Approaches to Infectious Disease Prediction and
- 477 Control. in *Risk and Optimization in an Uncertain World* (eds. Hasenbein, J. J., Gray, P. &

478 Greenberg, H. J.) 1–25 (INFORMS, 2010). doi:10.1287/educ.1100.0075.

- 479 29. Shayak, B., Sharma, M. M., Gaur, M. & Mishra, A. K. Impact of reproduction number on the
- 480 multiwave spreading dynamics of COVID-19 with temporary immunity: A mathematical model.
- 481 International Journal of Infectious Diseases 104, 649–654 (2021).
- 482 30. Fraser, C. *et al.* Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* 324,
  483 1557–1561 (2009).
- 484 31. Estimating influenza latency and infectious period durations using viral excretion data | Elsevier
  485 Enhanced Reader.
- 486 https://reader.elsevier.com/reader/sd/pii/S175543651200031X?token=DF4EFC60621620615100C9E
- 487 8B5311504ED8DA7405A562CAD9A24D35659688672D0B5FEE716C90EE49D195FE23A439CA
- 488 F&originRegion=us-east-1&originCreation=20220327211853 doi:10.1016/j.epidem.2012.06.001.
- 489 32. Diekmann, O., Heesterbeek, J. A. P. & Roberts, M. G. The construction of next-generation matrices
- 490 for compartmental epidemic models. J. R. Soc. Interface. 7, 873–885 (2010).

- 491 33. van den Driessche, P. Reproduction numbers of infectious disease models. *Infect Dis Model* 2, 288–
  492 303 (2017).
- 493 34. Khan, M. A., Khan, Y. & Islam, S. Complex dynamics of an SEIR epidemic model with saturated
- 494 incidence rate and treatment. *Physica A: Statistical Mechanics and its Applications* **493**, 210–227
- 495 (2018).
- 496 35. Vensim. https://vensim.com/.
- 497 36. U.S. Census Bureau QuickFacts: Indiana. https://www.census.gov/quickfacts/IN.
- 498 37. Kennedy, D. M., Zambrano, G. J., Wang, Y. & Neto, O. P. Modeling the effects of intervention
- 499 strategies on COVID-19 transmission dynamics. *Journal of Clinical Virology* **128**, 104440 (2020).
- 500 38. Maciejewski, R. et al. A pandemic influenza modeling and visualization tool. Journal of Visual
- 501 *Languages & Computing* **22**, 268–278 (2011).
- 502 39. Ke, R., Romero-Severson, E., Sanche, S. & Hengartner, N. Estimating the reproductive number R0 of
- 503 SARS-CoV-2 in the United States and eight European countries and implications for vaccination.
- 504 *Journal of Theoretical Biology* **517**, 110621 (2021).
- 40. Sanche, S. *et al.* High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome
- 506 Coronavirus 2 Volume 26, Number 7—July 2020 Emerging Infectious Diseases journal CDC.
  507 doi:10.3201/eid2607.200282.
- 41. Biggerstaff, M., Cauchemez, S., Reed, C., Gambhir, M. & Finelli, L. Estimates of the reproduction
  number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. *BMC Infect Dis* 14, 480 (2014).
- 511 42. Peek, K. Flu Has Disappeared for More Than a Year. *Scientific American*
- 512 https://www.scientificamerican.com/article/flu-has-disappeared-worldwide-during-the-covid513 pandemic1/.
- 43. Aleta, A. *et al.* Modelling the impact of testing, contact tracing and household quarantine on second
  waves of COVID-19. *Nat Hum Behav* 4, 964–971 (2020).
- 516 44. The Flu Season | CDC. https://www.cdc.gov/flu/about/season/flu-season.htm (2021).

- 517 45. Pinky, L. & Dobrovolny, H. M. SARS-CoV-2 coinfections: Could influenza and the common cold be
  518 beneficial? *Journal of Medical Virology* 92, 2623–2630 (2020).
- 46. Achdout, H. et al. Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by
- 520 influenza immunity but not SARS-CoV-2 immunity. *Nat Commun* **12**, 5819 (2021).
- 47. Lee, A. & Morling, J. COVID19: The need for public health in a time of emergency. *Public Health*
- **522 182**, 188–189 (2020).
- 48. What to Know about a 'Double-Barreled Flu Season'. *Healthline* https://www.healthline.com/healthnews/get-the-flu-twice-this-year (2020).
- 49. Mandal, M. *et al.* A model based study on the dynamics of COVID-19: Prediction and control.
- 526 *Chaos, Solitons & Fractals* **136**, 109889 (2020).
- 527 50. Doctor explains how one coronavirus patient can infect 59,000 others. *The Independent*
- 528 https://www.independent.co.uk/news/health/coronavirus-infections-symptoms-flu-doctor-dispatches-
- 529 a9419146.html (2020).
- 530 51. Using the SIR Model to Model the Spread of Influenza. UKDiss.com
- 531 https://ukdiss.com/examples/sir-model-spread-of-influenza.php.
- 532 52. Mortality Analyses Johns Hopkins Coronavirus Resource Center.
- 533 https://coronavirus.jhu.edu/data/mortality.
- 53. CDC. Burden of Influenza. *Centers for Disease Control and Prevention*
- 535 https://www.cdc.gov/flu/about/burden/index.html (2020).
- 536 54. Iacobucci, G. Covid-19: Risk of death more than doubled in people who also had flu, English data
- show. *BMJ* **370**, (2020).

# 1 Figures

- 2 Figure 1 illustrates the model described in Section 4.1. The corresponding dynamics are provided
- 3 in Equations 1 10.



- Figure 1 Schematic flow of the model, parameters and compartments are outlined in section 4.1 and dynamics are
   described in section 4.2. Different colors are utilized to indicated similar components.
- 7



Figure 2 – An overview of the compartments in the model. The smaller figures illustrate a closer comparison

- between similar compartments, for a 365-day simulation of the Co-infection of COVID-19 and Influenza.



3

Figure 3 – The effect of COVID-19 vaccine on the simulation results – lighter curves indicate smaller rate of 13 14 vaccination.



Figure 4 – The effect of quarantine and education on the simulation results – lighter curves indicate higher decrease 16

4

17 in the contact rates (1: no decrease in contact rates, 0.2: 20% of the maximum effective contact rate, etc.)